Harboe M
Institutt for generell og revmatologisk immunologi, Oslo.
Tidsskr Nor Laegeforen. 1992 Dec 10;112(30):3795-8.
Armauer Hansen described his first observation of Mycobacterium leprae on 28 February 1873 in detail. His discovery of the leprosy bacillus was the result of a logical process in which distinct stages can be clearly seen. The first step was clinical, and established criteria for leprosy as "a specific disease". The second stage was epidemiological. Contrary to the main view favouring a genetic basis, these observations convinced him of the infectious nature of the disease. The third stage was the search for the bacillus. His basic observations were reproduced, as documented. Armauer Hansen afterwards tried to fulfill Koch's postulates, in order to prove that the bacillus was the causative agent of leprosy. His second main contribution is the work on leprosy control, emphasizing isolation to contain the infection. The subsequent decline of leprosy in Norway differs from the trend in many developing countries, where leprosy has remained an important public health problem. In recent years Norwegian medical research has made significant contributions to leprosy research, in the field of epidemiology in Bergen, and through immunological studies of the disease originating from the Armauer Hansen Research Institute in Addis Ababa, Ethiopia.
阿马尔·汉森于1873年2月28日详细描述了他对麻风分枝杆菌的首次观察。他发现麻风杆菌是一个逻辑过程的结果，在这个过程中可以清晰地看到不同的阶段。第一步是临床阶段，确立了将麻风病作为“一种特定疾病”的标准。第二阶段是流行病学阶段。与支持遗传基础的主流观点相反，这些观察使他确信这种疾病具有传染性。第三阶段是寻找杆菌。他的基本观察结果得到了重现，有文献记载。阿马尔·汉森后来试图满足科赫法则，以证明该杆菌是麻风病的病原体。他的第二项主要贡献是在麻风病控制方面的工作，强调通过隔离来控制感染。挪威麻风病随后的下降情况与许多发展中国家的趋势不同，在这些发展中国家，麻风病仍然是一个重要的公共卫生问题。近年来，挪威医学研究在麻风病研究方面做出了重大贡献，在卑尔根的流行病学领域，以及通过源自埃塞俄比亚亚的斯亚贝巴阿马尔·汉森研究所的该疾病免疫学研究。
